Phases blog · Jul 2026
Explains how Phases approaches clinical-trial AI with security, compliance, and auditability as the core design constraints.
Automating clinical trials, starting with patient recruitment.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Phases is a San Francisco-based, YC-backed healthtech startup building AI agents for clinical trial operations, starting with Polly, an AI recruiter that automates patient outreach, prescreening, scheduling, and trial oversight.
Primary product
Polly, an AI recruiter and operations agent for clinical trials.
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10 employees
Industry
Healthcare IT
Sub-industry
Clinical trial operations and recruitment automation
Offices
0 jobs at Phases
Check back later for new openings
Business model
Stage
pre-seed
Total raised
$500K
Latest round
Pre-Seed · Oct 2025
Latest amount
$500K
Oct 2025 · Y Combinator
Leadership
Co-Founder & CEO
Co-Founder & Chief AI Officer
Co-Founder & CTO
Founder-led and security/compliance-first, with public messaging centered on auditability, controlled access, cited outputs, human escalation, and customer-specific data isolation for clinical operations.
Pricing
Not publicly listed; appears sales-led and demo/custom-contract based.
Differentiators
Technology
Customers
Competitors
Estimated revenue
~$330K estimated ARR (third-party estimate)
Estimated monthly visits
3.5K
Traffic estimate as of Jul 2026
Phases blog · Jul 2026
Explains how Phases approaches clinical-trial AI with security, compliance, and auditability as the core design constraints.
Phases blog · Jul 2026
Argues that clinical-trial agents need controlled access, cited outputs, independent verification, human escalation, and regression evals.
LinkedIn post · Jul 2026
Highlights a 21 CFR Part 11 audit-trail risk case and reinforces Phases' compliance positioning.
LinkedIn post · Jun 2026
Frames AI as a way to make trial review and follow-through much cheaper, enabling broader oversight at scale.
LinkedIn post · Jun 2026
Says generic copilots are insufficient for clinical development and that specialized agents are needed for ClinOps workflows.